Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma

por Carlo, M.I., Manley, B., Patil, S., Woo, K.M., Coskey, D.T., Redzematovic, A., Arcila, M., Ladanyi, M., Lee, W., Chen, Y.B., Lee, C.H., Feldman, D.R., Hakimi, A.A., Motzer, R.J., Hsieh, J.J., Voss, M.H.
Publicado 2017

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders

por Boilève, A., Carlo, M. I., Barthélémy, P., Oudard, S., Borchiellini, D., Voss, M. H., George, S., Chevreau, C., Landman-Parker, J., Tabone, M-D, Chism, D. D., Amin, A., Bilen, M. A., Bosse, D., Coulomb-L’hermine, A., Su, Xiaoping, Choueiri, T. K., Tannir, Nizar M., Malouf, Gabriel G.
Publicado 2018

IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies

por Barrios, D. M., Phillips, G. S., Geisler, A. N., Trelles, S. R., Markova, A., Noor, S. J., Quigley, E. A., Haliasos, H. C., Moy, A. P., Schram, A. M., Bromberg, J., Funt, S. A., Voss, M. H., Drilon, A., Hellmann, M. D., Comen, E. A., Narala, S., Patel, A. B., Wetzel, M., Jung, J. Y., Leung, D. Y. M., Lacouture, M. E.
Publicado 2021